The Pathologists' Conundrum-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The Pathologists' Conundrum

Published:2022-12-28 Issue:1 Volume:147 Page:17-18
ISSN:1543-2165
Container-title:Archives of Pathology & Laboratory Medicine
language:en
Short-container-title:

Author:

Rimm David L.¹,Dacic Sanja¹,Schnitt Stuart J.²³

Affiliation:

1. From the Department of Pathology, Yale University School of Medicine, New Haven, Connecticut (Rimm, Dacic)

2. The Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (Schnitt)

3. The Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts (Schnitt)

Publisher

Archives of Pathology and Laboratory Medicine

Subject

Medical Laboratory Technology,General Medicine,Pathology and Forensic Medicine

Link

https://meridian.allenpress.com/aplm/article-pdf/147/1/17/3171504/i1543-2165-147-1-17.pdf

Reference13 articles.

1. AACR Pathology Task Force. Pathology: hub and integrator of modern, multidisciplinary [precision] oncology. Clin Cancer Res. 2022; 28(2): 265– 270.

2. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999; 17(5): 1474– 1481.

3. Doroshow DB, Bhalla S, Beasley MB, et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2021; 18(6): 345– 362.

4. Rimm DL, Han G, Taube JM, et al. A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer. JAMA Oncol. 2017; 3(8): 1051– 1058.

5. Tsao MS, Kerr KM, Kockx M, et al. PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of Blueprint phase 2 project. J Thorac Oncol. 2018; 13(9): 1302– 1311.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. What will it take for histologists to be recognized under CLIA?;Journal of Histotechnology;2024-07-02

2. Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers Committee;Journal for ImmunoTherapy of Cancer;2024-07

3. High contrast breast cancer biomarker semi-quantification and immunohistochemistry imaging using upconverting nanoparticles;Biomedical Optics Express;2024-01-19

4. Predicting Response to Antibody Drug Conjugates: A Focus on Antigens’ Targetability;The Oncologist;2023-09-04

5. A Weakly Supervised Deep Learning Framework for Whole Slide Classification to Facilitate Digital Pathology in Animal Study;Chemical Research in Toxicology;2023-08-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3